• Je něco špatně v tomto záznamu ?

Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma

Elena Dementyeva, Fedor Kryukov, Lenka Kubiczkova, Pavel Nemec, Sabina Sevcikova, Ivana Ihnatova, Jiri Jarkovsky, Jiri Minarik, Zdena Stefanikova, Petr Kuglik, Roman Hajek

. 2013 ; 11 (-) : 77.

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc14051153

Grantová podpora
NT11154 MZ0 CEP - Centrální evidence projektů
NT12130 MZ0 CEP - Centrální evidence projektů
NT13190 MZ0 CEP - Centrální evidence projektů

BACKGROUND: Multiple myeloma (MM) is a low proliferative tumor of postgerminal center plasma cell (PC). Centrosome amplification (CA) is supposed to be one of the mechanisms leading to chromosomal instability. Also, CA is associated with deregulation of cell cycle, mitosis, DNA repair and proliferation. The aim of our study was to evaluate the prognostic significance and possible role of CA in pathogenesis and analysis of mitotic genes as mitotic disruption markers. DESIGN AND METHODS: A total of 173 patients were evaluated for this study. CD138+ cells were separated by MACS. Immunofluorescent labeling of centrin was used for evaluation of centrosome amplification in PCs. Interphase FISH with cytoplasmic immunoglobulin light chain staining (cIg FISH) and qRT-PCR were performed on PCs. RESULTS: Based on the immunofluorescent staining results, all patients were divided into two groups: CA positive (38.2%) and CA negative (61.8%). Among the newly diagnosed patients, worse overall survival was indicated in the CA negative group (44/74) in comparison to the CA positive group (30/74) (P = 0.019). Gene expression was significantly down-regulated in the CA positive group in comparison to CA negative in the following genes: AURKB, PLK4, TUBG1 (P < 0.05). Gene expression was significantly down-regulated in newly diagnosed in comparison to relapsed patients in the following genes: AURKA, AURKB, CCNB1, CCNB2, CETN2, HMMR, PLK4, PCNT, and TACC3 (P < 0.05). CONCLUSIONS: Our findings indicate better prognosis for CA positive newly diagnosed patients. Considering revealed clinical and gene expression heterogeneity between CA negative and CA positive patients, there is a possibility to characterize centrosome amplification as a notable event in multiple myeloma pathogenesis.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc14051153
003      
CZ-PrNML
005      
20200219092753.0
007      
ta
008      
140401s2013 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/1479-5876-11-77 $2 doi
035    __
$a (PubMed)23522059
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Kryukova, Elena $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0122005
245    10
$a Clinical implication of centrosome amplification and expression of centrosomal functional genes in multiple myeloma / $c Elena Dementyeva, Fedor Kryukov, Lenka Kubiczkova, Pavel Nemec, Sabina Sevcikova, Ivana Ihnatova, Jiri Jarkovsky, Jiri Minarik, Zdena Stefanikova, Petr Kuglik, Roman Hajek
520    9_
$a BACKGROUND: Multiple myeloma (MM) is a low proliferative tumor of postgerminal center plasma cell (PC). Centrosome amplification (CA) is supposed to be one of the mechanisms leading to chromosomal instability. Also, CA is associated with deregulation of cell cycle, mitosis, DNA repair and proliferation. The aim of our study was to evaluate the prognostic significance and possible role of CA in pathogenesis and analysis of mitotic genes as mitotic disruption markers. DESIGN AND METHODS: A total of 173 patients were evaluated for this study. CD138+ cells were separated by MACS. Immunofluorescent labeling of centrin was used for evaluation of centrosome amplification in PCs. Interphase FISH with cytoplasmic immunoglobulin light chain staining (cIg FISH) and qRT-PCR were performed on PCs. RESULTS: Based on the immunofluorescent staining results, all patients were divided into two groups: CA positive (38.2%) and CA negative (61.8%). Among the newly diagnosed patients, worse overall survival was indicated in the CA negative group (44/74) in comparison to the CA positive group (30/74) (P = 0.019). Gene expression was significantly down-regulated in the CA positive group in comparison to CA negative in the following genes: AURKB, PLK4, TUBG1 (P < 0.05). Gene expression was significantly down-regulated in newly diagnosed in comparison to relapsed patients in the following genes: AURKA, AURKB, CCNB1, CCNB2, CETN2, HMMR, PLK4, PCNT, and TACC3 (P < 0.05). CONCLUSIONS: Our findings indicate better prognosis for CA positive newly diagnosed patients. Considering revealed clinical and gene expression heterogeneity between CA negative and CA positive patients, there is a possibility to characterize centrosome amplification as a notable event in multiple myeloma pathogenesis.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a proliferace buněk $7 D049109
650    _2
$a separace buněk $7 D002469
650    _2
$a centrozom $x ultrastruktura $7 D018385
650    _2
$a oprava DNA $7 D004260
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a stanovení celkové genové exprese $7 D020869
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a hybridizace in situ fluorescenční $7 D017404
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mitóza $7 D008938
650    _2
$a mnohočetný myelom $x farmakoterapie $x genetika $7 D009101
650    _2
$a polymerázová řetězová reakce $7 D016133
650    _2
$a prognóza $7 D011379
650    _2
$a recidiva $7 D012008
650    _2
$a syndekan-1 $x metabolismus $7 D053668
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kryukov, Fedor $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0128646
700    1_
$a Bešše, Lenka $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2014851432
700    1_
$a Němec, Pavel $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 xx0162732
700    1_
$a Ševčíková, Sabina, $d 1972- $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 mub2015859787
700    1_
$a Ihnatova, Ivana $u Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Jarkovský, Jiří $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Institute for Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic $7 stk2008461294
700    1_
$a Minařík, Jiří $u Department of Internal Medicine, University Hospital Olomouc, Olomouc, Czech Republic $7 xx0106330
700    1_
$a Štefániková, Zdenka $u Department of Hematology and Blood Transfusion, University Hospital Bratislava, Bratislava, Slovak Republic $7 xx0127146
700    1_
$a Kuglík, Petr, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic; Integrated Laboratory of Molecular Cytogenetics, Department of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic $d 1957- $7 ola2003204793
700    1_
$a Hájek, Roman, $u Babak Myeloma Group, Department of Pathological Physiology, Faculty of Medicine, Masaryk University, Brno, Czech Republic $d 1964- $7 nlk20000083645
773    0_
$w MED00008239 $t Journal of translational medicine $x 1479-5876 $g Roč. 11, č. - (2013), s. 77
856    41
$u https://pubmed.ncbi.nlm.nih.gov/23522059 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20140401 $b ABA008
991    __
$a 20200219093155 $b ABA008
999    __
$a ok $b bmc $g 1018289 $s 849733
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2013 $b 11 $c - $d 77 $i 1479-5876 $m Journal of translational medicine $n J Transl Med $x MED00008239
GRA    __
$a NT11154 $p MZ0
GRA    __
$a NT12130 $p MZ0
GRA    __
$a NT13190 $p MZ0
LZP    __
$a Pubmed-20140401

Najít záznam

Citační ukazatele

Možnosti archivace